Receptor subtype and outcome of breast cancer - Single-center experience from North India.

Autor: Banday SZ; Department of Medical Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Ayub M; Department of Pathology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Rasool MT; Department of Radiation Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Ahmed SZ; Department of Surgical Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Banday AZ; Department of Pediatrics, Government Medical College (GMC), Srinagar, Jammu and Kashmir, India., Naveed S; Department of Surgical Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Guru FR; Department of Medical Oncology (Pediatrics), State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Mir MH; Department of Medical Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Akhter S; Department of Pathology, Government Medical College (GMC), Srinagar, Jammu and Kashmir, India., Bhat MH; Department of Radiodiagnosis and Imaging, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Yaseen SB; Department of Pathology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Afroz F; Department of Radiation Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Bhat GM; Department of Medical Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Lone MM; Department of Radiation Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India., Aziz SA; Department of Medical Oncology, State Cancer Institute (SCI), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India.
Jazyk: angličtina
Zdroj: Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Jul 01; Vol. 20 (5), pp. 1486-1493. Date of Electronic Publication: 2024 Jan 22.
DOI: 10.4103/jcrt.jcrt_56_23
Abstrakt: Aims/objectives: In resource-limited settings, data regarding the impact of molecular/receptor subtypes on breast cancer (BC) are sparse. In this single-center retrospective study from north India, we analyze the outcomes of various molecular subtypes of BC.
Materials and Methods: Females with biopsy-proven BC who were treated at our State Cancer Institute from 2014-2018 were included. Data regarding clinicopathological parameters and follow-up details were evaluated. For data analysis, cancers were categorized into 4 subtypes: HR+HER2-, HR+HER2+, HR-HER2+, and HR-HER2-.
Results: Among 944 patients included, HR+HER2- (49.1%) and HR+HER2+ (13.1%) were the most and least common subtypes, respectively. The receptor subtype significantly impacted overall survival (OS). HR+HER2- cancers had the best outcomes while HR-HER2- cancers fared worst (3-yr OS of 94.3% and 69.1%, respectively). On subgroup analysis, the molecular subtype continued to significantly impact OS in patients with tumor grades II and III, disease stages II and III, and age groups of <40 and 40-60 years, respectively (HR-HER2- cancers had the lowest cumulative survival in each subgroup). In patients with metastatic BC, all molecular subtypes except HR+HER2- had a dismal prognosis.
Conclusions: Overall and across various subgroups, patients with triple-negative BC had the poorest outcomes. Ensuring optimal treatment utilization including affordable access to personalized tailored therapy is the need of the hour to improve long-term outcomes in these patients.
(Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje